Edurant (rilpivirine) is a non-nucleoside reverse transcriptase inhibitor used to treat HIV/AIDS. It is approved by the U.S. FDA for the treatment of HIV infection in adults. It is listed in the DHHS HIV treatment guidelines as part of an alternative regimen for people starting HIV treatment for the first time with an HIV viral load less than 100,000 copies/mL. Edurant should be taken in combination with Epzicom or Combivir.
Adult single dose: Take one tablet once daily. Each tablet contains 25 mg.
News & Research